Pharsight

Diabetology Therapeutics

1. Avandamet patents expiration

Treatment: Treatment of type 2 diabetes mellitus

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5741803 SB PHARMCO Substituted thiazolidinedionle derivatives
Apr, 2015

(9 years ago)

US5965584 SB PHARMCO Pharmaceutical composition
Jun, 2016

(7 years ago)

US6166042 SB PHARMCO Pharmaceutical composition
Jun, 2016

(7 years ago)

US6288095 SB PHARMCO Compounds
Feb, 2017

(7 years ago)

Drugs and Companies using METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE ingredient

Market Authorisation Date: 25 August, 2003

Dosage: TABLET;ORAL

How can I launch a generic of AVANDAMET before it's drug patent expiration?
More Information on Dosage

AVANDAMET family patents

Family Patents

2. Brenzavvy patents expiration

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8802637 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(4 years from now)

US7838499 THERACOSBIO Benzylbenzene derivatives and methods of use
Jan, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8106021 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(4 years from now)

US10533032 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jul, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 20 January, 2027

Market Authorisation Date: 20 January, 2023

Dosage: TABLET;ORAL

More Information on Dosage

BRENZAVVY family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Bydureon patents expiration

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve gl...

BYDUREON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(a month ago)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(1 year, 30 days from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

Family Patents

4. Bydureon Bcise patents expiration

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; As an adjunct to diet and exer...

BYDUREON BCISE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6872700 ASTRAZENECA AB Methods for glucagon suppression
Jan, 2020

(4 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(a month ago)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(1 year, 30 days from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8895033 ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jul 22, 2024
Pediatric Exclusivity(PED) Jan 22, 2025
M(M-240) Feb 15, 2022
New Product(NP) Oct 20, 2020

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

Family Patents

5. Bydureon Pen patents expiration

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; As an adjunct to diet and exer...

BYDUREON PEN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6872700 ASTRAZENECA AB Methods for glucagon suppression
Jan, 2020

(4 years ago)

US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(a month ago)

US7612176 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(1 year, 30 days from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Jan 22, 2025
New Patient Population(NPP) Jul 22, 2024
M(M-240) Feb 15, 2022
M(M-162) Sep 24, 2018
M(M-212) Oct 20, 2020
M(M-224) Apr 02, 2021
New Product(NP) Jan 27, 2015

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON PEN family patents

Family Patents

6. Cycloset patents expiration

Treatment: Improvement of glycemic control in individuals with type 2 diabetes; Treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined th...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866584 VEROSCIENCE Therapeutic process for the treatment of the pathologies of type II diabetes
Nov, 2012

(11 years ago)

US5756513 VEROSCIENCE Therapeutic process for the treatment of the pathologies of type II diabetes
Nov, 2012

(11 years ago)

US5468755 VEROSCIENCE Therapeutic process for the treatment of the pathologies of Type II diabetes
Nov, 2012

(11 years ago)

US5716957 VEROSCIENCE Method for modifying and resetting the bloodstream prolactin levels of a human subject
Feb, 2015

(9 years ago)

US7888310 VEROSCIENCE Methods of identifying responders to dopamine agonist therapy
Jul, 2023

(10 months ago)

US8877708 VEROSCIENCE Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US9895422 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US9352025 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US10688155 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(6 years from now)

US8431155 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9192576 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9700555 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9522117 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US9993474 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

US8613947 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 05, 2012

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Market Authorisation Date: 05 May, 2009

Dosage: TABLET;ORAL

More Information on Dosage

CYCLOSET family patents

Family Patents

7. Farxiga patents expiration

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) ...

FARXIGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(a month ago)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(10 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(1 year, 30 days from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

US11826376 ASTRAZENECA AB Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
Jul, 2039

(15 years from now)

US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
M(M-238) Feb 22, 2022
New Indication(I-834) May 05, 2023
M(M-212) Oct 20, 2020
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-157) Mar 11, 2018
New Indication(I-841) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 08 January, 2014

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

8. Glyxambi patents expiration

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...

GLYXAMBI's oppositions filed in EPO
GLYXAMBI IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US6890898 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(2 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(2 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(5 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(6 years from now)

US10406172 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2030

(6 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-739) Dec 02, 2019
New Combination(NC) Jan 30, 2018
M(M-258) Jul 03, 2022
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-252) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

NCE-1 date: 01 August, 2018

Market Authorisation Date: 30 January, 2015

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage

GLYXAMBI family patents

Family Patents

9. Inpefa patents expiration

Treatment: Reduction of risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardi...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7781577 LEXICON PHARMS INC Inhibitors of sodium glucose co-transporter 2 and methods of their use
May, 2028

(3 years from now)

US8476413 LEXICON PHARMS INC Sulfanyl-tetrahydropyran-based compounds and methods of their use
May, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 26, 2028

Drugs and Companies using SOTAGLIFLOZIN ingredient

NCE-1 date: 27 May, 2027

Market Authorisation Date: 26 May, 2023

Dosage: TABLET;ORAL

More Information on Dosage

INPEFA family patents

Family Patents

10. Invokamet patents expiration

Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients

INVOKAMET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(10 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-735) May 20, 2019
New Combination(NC) Aug 08, 2017
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 08 August, 2014

Dosage: TABLET;ORAL

How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage

INVOKAMET family patents

Family Patents

11. Invokamet Xr patents expiration

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Treatment of type 2 diabetes mellitus

INVOKAMET XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(10 months from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Aug 08, 2017
New Indication(I-735) May 20, 2019
New Chemical Entity Exclusivity(NCE) Mar 29, 2018
New Indication(I-788) Oct 29, 2021

Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 20 September, 2016

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage

INVOKAMET XR family patents

Family Patents

12. Invokana patents expiration

Treatment: Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascu...

INVOKANA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(3 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(10 months from now)

US10617668 JANSSEN PHARMS Pharmaceutical formulations
May, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-809) Sep 27, 2022
New Indication(I-733) May 20, 2019
M(M-197) Feb 01, 2020
New Indication(I-788) Oct 29, 2021
New Chemical Entity Exclusivity(NCE) Mar 29, 2018

Drugs and Companies using CANAGLIFLOZIN ingredient

NCE-1 date: 29 March, 2017

Market Authorisation Date: 29 March, 2013

Dosage: TABLET;ORAL

How can I launch a generic of INVOKANA before it's drug patent expiration?
More Information on Dosage

INVOKANA family patents

Family Patents

13. Janumet patents expiration

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...

JANUMET's oppositions filed in EPO
JANUMET IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 MSD SUB MERCK Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US7459428 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6699871 MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

US7125873 MSD SUB MERCK Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

US8414921 MSD SUB MERCK Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jul, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-187) Dec 04, 2023
Pediatric Exclusivity(PED) Jun 04, 2024
New Chemical Entity Exclusivity(NCE) Oct 16, 2011
M(M-244) Aug 12, 2022

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: 05 June, 2023

Market Authorisation Date: 30 March, 2007

Dosage: TABLET;ORAL

How can I launch a generic of JANUMET before it's drug patent expiration?
More Information on Dosage

JANUMET family patents

Family Patents

14. Janumet Xr patents expiration

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate

JANUMET XR's oppositions filed in EPO
JANUMET XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 MSD SUB MERCK Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US7078381 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 MSD SUB MERCK Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7125873 MSD SUB MERCK Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

US6699871 MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-187) Dec 04, 2023
Pediatric Exclusivity(PED) Feb 12, 2023
M(M-244) Aug 12, 2022

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 02 February, 2012

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JANUMET XR before it's drug patent expiration?
More Information on Dosage

JANUMET XR family patents

Family Patents

15. Januvia patents expiration

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...

JANUVIA's oppositions filed in EPO
JANUVIA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 MERCK SHARP DOHME Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US7078381 MERCK SHARP DOHME Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 MERCK SHARP DOHME Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-187) Dec 04, 2023
Pediatric Exclusivity(PED) Jun 04, 2024
New Chemical Entity Exclusivity(NCE) Oct 16, 2011
M(M-244) Aug 12, 2022

Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: 05 June, 2023

Market Authorisation Date: 16 October, 2006

Dosage: TABLET;ORAL

How can I launch a generic of JANUVIA before it's drug patent expiration?
More Information on Dosage

JANUVIA family patents

Family Patents

16. Jardiance patents expiration

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...

JARDIANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(5 years from now)

US10406172 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2030

(6 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 20, 2026
New Indication(I-869) Aug 18, 2024
New Indication(I-922) Sep 21, 2026
M(M-82) Feb 24, 2025
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-159) Jun 26, 2018
New Indication(I-739) Dec 02, 2019
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-160) Jun 26, 2018
M(M-161) Jun 26, 2018
M(M-174) Mar 18, 2019

Drugs and Companies using EMPAGLIFLOZIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 01 August, 2014

Dosage: TABLET;ORAL

How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage

JARDIANCE family patents

Family Patents

17. Jentadueto patents expiration

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in co...

JENTADUETO's oppositions filed in EPO
JENTADUETO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(2 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(2 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-146) Jul 30, 2017
M(M-252) Mar 30, 2023
M(M-258) Jul 03, 2022
New Combination(NC) Jan 30, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 30 January, 2012

Dosage: TABLET;ORAL

How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage

JENTADUETO family patents

Family Patents

18. Jentadueto Xr patents expiration

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in co...

JENTADUETO XR's oppositions filed in EPO
JENTADUETO XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US7459428 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(2 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(2 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(6 years from now)

US9555001 BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Mar, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-252) Mar 30, 2023
M(M-258) Jul 03, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage

JENTADUETO XR family patents

Family Patents

19. Juvisync patents expiration

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate; Method of treating type 2 diabetes mellitus in patients for whom treatm...

JUVISYNC's oppositions filed in EPO
JUVISYNC IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Apr, 2026

(1 year, 10 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 MERCK SHARP DOHME Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US7459428 MERCK SHARP DOHME Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 MERCK SHARP DOHME Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 MERCK SHARP DOHME Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8168637 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes
Jun, 2022

(1 year, 11 months ago)

US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 18 September, 2012

Dosage: TABLET;ORAL

More Information on Dosage

JUVISYNC family patents

Family Patents

20. Kombiglyze Xr patents expiration

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate

KOMBIGLYZE XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6395767 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Feb, 2021

(3 years ago)

USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-134) May 24, 2016
M(M-175) Apr 05, 2019
M(M-198) Feb 27, 2020
New Chemical Entity Exclusivity(NCE) Jul 31, 2014

Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2013

Market Authorisation Date: 05 November, 2010

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of KOMBIGLYZE XR before it's drug patent expiration?
More Information on Dosage

KOMBIGLYZE XR family patents

Family Patents

21. Mounjaro patents expiration

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 July, 2023

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

MOUNJARO family patents

Family Patents

22. Mounjaro (autoinjector) patents expiration

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 July, 2023

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

MOUNJARO (AUTOINJECTOR) family patents

Family Patents

23. Onglyza patents expiration

Treatment: Method for treating type ii diabetes by administering saxagliptin

ONGLYZA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6395767 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Feb, 2021

(3 years ago)

USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-134) May 24, 2016
M(M-175) Apr 05, 2019
M(M-198) Feb 27, 2020
New Chemical Entity Exclusivity(NCE) Jul 31, 2014
M(M-108) Dec 16, 2014

Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2013

Market Authorisation Date: 31 July, 2009

Dosage: TABLET;ORAL

How can I launch a generic of ONGLYZA before it's drug patent expiration?
More Information on Dosage

ONGLYZA family patents

Family Patents

24. Ozempic patents expiration

What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indicated as an adjunct to diet and exercise to imp...

OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(1 year, 9 months from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335462 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-185) Mar 28, 2025
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
New Indication(I-822) Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 05 December, 2017

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

25. Qtern patents expiration

Treatment: Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; Treatment of type 2 diabetes mellitus

QTERN's oppositions filed in EPO
QTERN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-175) Apr 05, 2019
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
New Combination(NC) Feb 27, 2020
New Strength(NS) May 02, 2022
New Indication(I-804) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 02 May, 2019

Dosage: TABLET;ORAL

How can I launch a generic of QTERN before it's drug patent expiration?
More Information on Dosage

QTERN family patents

Family Patents

26. Qternmet Xr patents expiration

Treatment: Treatment of type 2 diabetes mellitus

QTERNMET XR's oppositions filed in EPO
QTERNMET XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 02, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 02 May, 2019

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

QTERNMET XR family patents

Family Patents

27. Qulipta patents expiration

Treatment: Preventive treatment of migraine in adults

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9499545 ABBVIE Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(7 years from now)

US8754096 ABBVIE Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-909) Apr 17, 2026
New Chemical Entity Exclusivity(NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: 28 September, 2025

Market Authorisation Date: 28 September, 2021

Dosage: TABLET;ORAL

More Information on Dosage

QULIPTA family patents

Family Patents

28. Rybelsus patents expiration

Treatment: Method of treating type 2 diabetes mellitus

RYBELSUS's oppositions filed in EPO
RYBELSUS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(1 year, 9 months from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278123 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(7 years from now)

US10278923 NOVO Oral dosing of GLP-1 compounds
May, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 20, 2022
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
M(M-252) Jan 16, 2023

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 20 September, 2019

Dosage: TABLET;ORAL

More Information on Dosage

RYBELSUS family patents

Family Patents

29. Saxenda patents expiration

Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease

SAXENDA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968659 NOVO Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Dec 04, 2023
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

30. Segluromet patents expiration

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080580 MSD SUB MERCK Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439902 MSD SUB MERCK Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-275) Sep 17, 2024
New Chemical Entity Exclusivity(NCE) Dec 19, 2022

Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 19 December, 2021

Market Authorisation Date: 19 December, 2017

Dosage: TABLET;ORAL

More Information on Dosage

SEGLUROMET family patents

Family Patents

31. Steglatro patents expiration

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080580 MSD SUB MERCK Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-275) Sep 17, 2024
New Chemical Entity Exclusivity(NCE) Dec 19, 2022

Drugs and Companies using ERTUGLIFLOZIN ingredient

NCE-1 date: 19 December, 2021

Market Authorisation Date: 19 December, 2017

Dosage: TABLET;ORAL

How can I launch a generic of STEGLATRO before it's drug patent expiration?
More Information on Dosage

STEGLATRO family patents

Family Patents

32. Steglujan patents expiration

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

STEGLUJAN's oppositions filed in EPO
STEGLUJAN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6699871 MSD SUB MERCK Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(1 year, 10 months ago)

US7326708 MSD SUB MERCK Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(2 years from now)

US8080580 MSD SUB MERCK Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439901 MSD SUB MERCK Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-275) Sep 17, 2024
New Chemical Entity Exclusivity(NCE) Dec 19, 2022

Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient

NCE-1 date: 19 December, 2021

Market Authorisation Date: 19 December, 2017

Dosage: TABLET;ORAL

More Information on Dosage

STEGLUJAN family patents

Family Patents

33. Synjardy patents expiration

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Treating typ...

SYNJARDY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11813275 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
New Indication(I-739) Dec 02, 2019
New Product(NP) Aug 26, 2018
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-174) Mar 18, 2019

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 26 August, 2015

Dosage: TABLET;ORAL

How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage

SYNJARDY family patents

Family Patents

34. Synjardy Xr patents expiration

Treatment: Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagli...

SYNJARDY XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(7 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11813275 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-296) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 09 December, 2016

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage

SYNJARDY XR family patents

Family Patents

35. Tradjenta patents expiration

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (...

TRADJENTA's oppositions filed in EPO
TRADJENTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US7459428 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(2 years from now)

US9486526 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(5 years from now)

US10034877 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(5 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(6 years from now)

US8853156 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Mar, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-252) Mar 30, 2023
M(M-258) Jul 03, 2022
M(M-121) Aug 13, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016
M(M-118) Aug 13, 2015

Drugs and Companies using LINAGLIPTIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 02 May, 2011

Dosage: TABLET;ORAL

How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage

TRADJENTA family patents

Family Patents

36. Trijardy Xr patents expiration

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes using a pharmaceutical composition comprisi...

TRIJARDY XR's oppositions filed in EPO
TRIJARDY XR IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(9 months ago)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(2 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(2 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(5 years from now)

US10406172 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2030

(6 years from now)

US11564886 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(7 years from now)

US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(7 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage

TRIJARDY XR family patents

Family Patents

37. Vascepa patents expiration

Treatment: Use of vascepa as an adjunct to statin therapy to reduce the risk of myocardial infarction, stroke, both in an adult patient with type 2 diabetes mellitus; Use of vascepa as an adjunct to statin thera...

VASCEPA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792267 AMARIN PHARMS Methods of treating mixed dyslipidemia
Apr, 2030

(5 years from now)

US10278937 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US11369582 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(9 years from now)

US10668042 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(9 years from now)

US10576054 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(9 years from now)

US10786478 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(9 years from now)

US10894028 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 26, 2017
New Indication(I-819) Dec 13, 2022
New Product(NP) Jul 26, 2015

Drugs and Companies using ICOSAPENT ETHYL ingredient

NCE-1 date: 26 July, 2016

Market Authorisation Date: 26 July, 2012

Dosage: CAPSULE;ORAL

How can I launch a generic of VASCEPA before it's drug patent expiration?
More Information on Dosage

VASCEPA family patents

Family Patents

38. Victoza patents expiration

Treatment: A method for improving glycemic control in adults with type 2 diabetes mellitus; Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults...

VICTOZA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6458924 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US6268343 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-176) Apr 22, 2019
New Patient Population(NPP) Jun 17, 2022
New Indication(I-750) Aug 25, 2020
Pediatric Exclusivity(PED) Dec 17, 2022
M(M-115) Apr 06, 2015
New Chemical Entity Exclusivity(NCE) Jan 25, 2015

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage

VICTOZA family patents

Family Patents

39. Welchol patents expiration

Treatment: A method for reducing serum glucose levels in adults with type 2 diabetes mellitus

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7229613 COSETTE Method for lowering serum glucose
Apr, 2022

(2 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-608) Oct 02, 2012
Pediatric Exclusivity(PED) Apr 02, 2013

Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient

Market Authorisation Date: 26 May, 2000

Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL; BAR, CHEWABLE;ORAL

How can I launch a generic of WELCHOL before it's drug patent expiration?
More Information on Dosage

WELCHOL family patents

Family Patents

40. Xigduo Xr patents expiration

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazo...

XIGDUO XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(3 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(3 years ago)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(3 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
New Indication(I-841) Oct 18, 2022
M(M-238) Feb 22, 2022

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 08 January, 2018

Market Authorisation Date: 28 July, 2017

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of XIGDUO XR before it's drug patent expiration?
More Information on Dosage

XIGDUO XR family patents

Family Patents